Shattuck Labs, Inc. (STTK)
- Previous Close
7.26 - Open
7.20 - Bid 7.00 x 200
- Ask 7.08 x 200
- Day's Range
7.02 - 7.45 - 52 Week Range
1.33 - 11.76 - Volume
117,096 - Avg. Volume
313,169 - Market Cap (intraday)
333.807M - Beta (5Y Monthly) 1.86
- PE Ratio (TTM)
-- - EPS (TTM)
-1.93 - Earnings Date Aug 8, 2024 - Aug 12, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
15.50
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.
www.shattucklabs.comRecent News: STTK
Performance Overview: STTK
Trailing total returns as of 6/7/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: STTK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: STTK
Valuation Measures
Market Cap
333.81M
Enterprise Value
223.19M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
115.40
Price/Book (mrq)
2.59
Enterprise Value/Revenue
82.21
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-34.74%
Return on Equity (ttm)
-59.40%
Revenue (ttm)
2.71M
Net Income Avi to Common (ttm)
-85.08M
Diluted EPS (ttm)
-1.93
Balance Sheet and Cash Flow
Total Cash (mrq)
114.63M
Total Debt/Equity (mrq)
3.12%
Levered Free Cash Flow (ttm)
-41.48M